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The effect of cross-sex hormonal treatment 
on gender dysphoria individuals’ mental health: 
a systematic review
Rosalia Costa1
Marco Colizzi2
1Gender identity Development 
Service, Tavistock and Portman NHS 
Foundation Trust, Tavistock Centre, 
2Department of Psychosis Studies, 
institute of Psychiatry, Psychology & 
Neuroscience, King’s College London, 
London, UK
Abstract: Cross-sex hormonal treatment represents a main aspect of gender dysphoria health 
care pathway. However, it is still debated whether this intervention translates into a better mental 
well-being for the individual and which mechanisms may underlie this association. Although sex 
reassignment surgery has been the subject of extensive investigation, few studies have specifi-
cally focused on hormonal treatment in recent years. Here, we systematically review all studies 
examining the effect of cross-sex hormonal treatment on mental health and well-being in gender 
dysphoria. Research tends to support the evidence that hormone therapy reduces symptoms of 
anxiety and dissociation, lowering perceived and social distress and improving quality of life 
and self-esteem in both male-to-female and female-to-male individuals. Instead, compared to 
female-to-male individuals, hormone-treated male-to-female individuals seem to benefit more 
in terms of a reduction in their body uneasiness and personality-related psychopathology and 
an amelioration of their emotional functioning. Less consistent findings support an association 
between hormonal treatment and other mental health-related dimensions. In particular, depres-
sion, global psychopathology, and psychosocial functioning difficulties appear to reduce only 
in some studies, while others do not suggest any improvement in these domains. Results from 
longitudinal studies support more consistently the association between hormonal treatment and 
improved mental health. On the contrary, a number of cross-sectional studies do not support this 
evidence. This review provides possible biological explanation vs psychological explanation 
(direct effect vs indirect effect) for the hormonal treatment-induced better mental well-being. 
In conclusion, this review indicates that gender dysphoria-related mental distress may benefit 
from hormonal treatment intervention, suggesting a transient reaction to the nonsatisfaction 
connected to the incongruent body image rather than a stable psychiatric comorbidity. In this 
perspective, timely hormonal treatment intervention represents a crucial issue in gender dys-
phoria individuals’ mental health-related outcome.
Keywords: estrogen, testosterone, transsexualism, psychiatry, psychosocial wellbeing
Introduction
A strong and persistent cross-gender identification as well as a persistent discomfort 
with one’s natal sex or a sense of inappropriateness in the gender role of that sex has 
been considered as a core aspect of nonconforming gender identity since the first inclu-
sion of the condition in the Diagnostic and Statistical Manual of Mental Disorders 
(DSM) of the American Psychiatric Association.1 Until the last DSM revision,2 the 
condition has been known as “transsexualism/gender identity disorder”.1,3,4 In 2013, the 
American Psychiatric Association has significantly revised the condition definition in 
an attempt to balance between the competing issues of depathologizing nonconforming 
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gender identity vs access to care.2,5 As a consequence, the 
condition has been renamed “gender dysphoria” in order to 
imply a diagnostic entity in its own right, not necessarily 
associated with severe comorbid psychiatric findings, and 
better characterize the gender incongruence-related experi-
ence and discomfort.2 However, psychiatric comorbidity 
among individuals with gender dysphoria is still a matter of 
discussion. Some studies have reported a high prevalence of 
major psychiatric disorders in gender dysphoria.6–8 Instead, 
other research suggests a low level of psychopathology.9–11 A 
recent review has concluded that gender dysphoria individu-
als appear to have a higher risk of psychiatric comorbidity.12 
However, as reported by the authors, many studies were 
methodologically weak, and sex reassignment procedures 
appeared to be beneficial in reducing mental distress.12 
Therefore, the lack of consistency between studies about 
gender dysphoria individuals’ psychiatric comorbidity could 
be partially explained by their design, which usually did not 
explore the role of the lack of treatment in gender dysphoria 
individuals’ mental distress.
For most gender dysphoria individuals, the subjective 
experience of persistent cross-gender identification and dis-
comfort with their natal sex may be a stressful situation and 
cause clinical distress or impairment in important areas of 
functioning.9,13,14 Suffering from severe gender incongruence 
usually leads individuals to pursue hormone treatment and 
sex reassignment surgery. The purpose of these sex reassign-
ment procedures is to alleviate the individual’s distress by 
reducing the discrepancy between the individuals’ biological 
sex and their experience.15 Over the last few decades, research 
has prevalently focused on the effect of sex reassignment sur-
gery on gender dysphoria individuals’ mental health. In par-
ticular, previous research has suggested that sex reassignment 
surgery improves gender dysphoria individuals’ well-being, 
increasing their personal and general satisfaction,16–18 self-
confidence with body image,19–22 and quality of life.23–26 In 
contrast, the role of the cross-sex hormonal treatment in the 
well-being of gender dysphoria individuals has been the 
subject of relatively little investigation. A 2010 meta-analysis 
has identified 28 observational studies of the effect of sex 
reassignment on gender dysphoria individuals’ well-being.27 
However, only five studies specifically examined the impact 
of hormonal treatment and two of them focused on gender-
related cognitive aspects, which could be influenced by cross-
sex hormones and per se do not inform on hormone-treated 
individuals’ mental health or well-being.28,29 The remaining 
three studies addressed the effect of hormonal treatment 
on gender dysphoria individuals’ psychological profile,30 
emotional repercussions,31 and transformation satisfaction.32 
However, due to its design, the latter one32 could not infer 
an association between hormonal treatment and better trans-
formation satisfaction.
Studying the effect of cross-sex hormonal treatment on 
mental health in gender dysphoria may help to disentangle 
the burden of psychiatric comorbidity among individuals suf-
fering from this condition. In recent years, a larger body of 
evidence has accumulated from studies on the specific effect 
of hormonal treatment on different mental health-related 
outcome measures. The purpose of this review is to bring 
together and discuss all available data generated by cross-
sectional and longitudinal studies that have investigated the 
effect of hormone therapy on mental health by carrying out 
a systematic literature search for all such data.
Materials and methods
inclusion/exclusion criteria
Inclusion criteria for studies were as follows: 1) studies 
in gender dysphoria, 2) studies investigating the mid/
long-term effects of cross-sex hormonal treatment, and 
3) studies measuring mental health-related parameters, 
including a) depression, b) anxiety, c) personality, d) quality 
of life, e) dissociative symptoms, f) psychopathology, 
g) psychosocial/emotional functioning, h) distress, and 
i) self-esteem. Exclusion criteria were as follows: 1) studies 
in which cross-sex hormonal treatment was not the interven-
tion of interest (ie, studies including cross-sex hormonal 
treatment only as a confounder/covariate of no interest) and 
2) studies in which the mental health-related outcomes were 
not directly reported upon.
Search strategy
A final search was undertaken on May 16, 2016. The search 
terms used were as follows: (gender dysphoria or gender 
identity disorder or transsexualism) and (hormon* or cross-
sex hormonal treatment or hormone therapy) and (psych* or 
psychiatry or psychopathology or mental health or anxiety 
or depression). This search was undertaken in Medline, 
EMBASE, and PsycINFO using the OvidSP platform. All 
studies published in any language and indexed in the above 
databases were included. Reference lists from all identified 
relevant studies, reviews, and conference abstracts were 
screened for any additional relevant studies.
Data extraction
Demographic and methodological variables and outcome 
data for studies identified were extracted into a spreadsheet. 
Primary outcomes of interest were mental health-related 
parameters. These were compared within hormone-treated 
Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1955
Hormonal treatment and mental health in gender dysphoria
cohorts and/or between hormone-treated and nonhormone-
treated control groups.
Risk of bias
Risk of bias and quality assessment of the methodologically 
heterogeneous group of studies (Table 1) reviewed here 
required a suitably inclusive and flexible approach. For this 
purpose, an adapted set of criteria, suggested by the Agency 
for Healthcare Research and Quality guidance,33 amended as 
appropriate for observational studies in humans were used 
(Table 2). Risk of systematic bias across studies was further 
identified by assessing all articles for possible confounding 
factors, such as study population definition, mental health 
comorbidity, attrition, comparability of subjects, cross-sex 
hormonal treatment duration, type, and dosage (Table 3).
Results
Study selection
In total, 680 records were identified. All abstracts of the 
records were screened against the inclusion and exclusion 
criteria. A final list of 17 studies was identified for system-
atic analysis in this review. Cumulatively, the included 
studies investigated different aspects of mental health 
(Table 1) in response to cross-sex hormonal treatment, 
using both independent-groups (cross-sectional studies) 
and repeated measures (longitudinal studies) designs. 
These include 1) depression, mood states, and self-esteem; 
2) anxiety and tension; 3) global and personality-related 
psychopathology; 4) mental health-related quality of life; 5) 
dissociative symptoms; 6) psychosocial, interpersonal, and 
emotional functioning; and 7) social distress, perceived stress, 
Table 1 Studies included in the review
Study Type of study Target population(s) Mental health parameters
Bonierbale et al42 Cross-sectional study GiD adults with CSHT vs GiD adults 
without CSHT
Personality-related psychopathology
Bouman et al38 Cross-sectional study MtF adults with CSHT vs MtF adults 
without CSHT
Anxiety, depression, self-esteem, and 
interpersonal functioning
Colizzi et al45 Longitudinal study GD adults before and after CSHT Dissociative symptoms
Colizzi et al37 Longitudinal study GiD adults before and after CSHT Anxiety, depression, psychopathological 
symptoms, and psychosocial functioning
Fisher et al39 Cross-sectional study GD adults with CSHT vs GD adults 
without CSHT
Body uneasiness and 
psychopathological symptoms 
Gómez-Gil et al44 Cross-sectional study GiD adults with CSHT vs GiD adults 
without CSHT
Mental health-related quality of life
Heylens et al40 Longitudinal study GiD adults before and after CSHT Psychopathological symptoms
Colizzi et al14 Longitudinal study GiD adults before and after CSHT Perceived stress
Gorin-Lazard et al36 Cross-sectional study GiD adults with CSHT vs GiD adults 
without CSHT
Self-esteem, depression, quality of life, 
and psychosocial functioning
Gómez-Gil et al35 Cross-sectional study GiD adults with CSHT vs GiD adults 
without CSHT 
Social distress, anxiety, and depression
Gorin-Lazard et al43 Cross-sectional study GiD adults with CSHT vs GiD adults 
without CSHT
Mental health-related quality of life
Gómez-Gil et al41 Cross-sectional study GiD adults with CSHT vs GiD adults 
without CSHT
Personality-related psychopathology
Miles et al29 1. Longitudinal study
2. Longitudinal study
3. Longitudinal study
4. Cross-sectional study
1. MtF GiD adults before and after CSHT
2. MtF GiD adults with CSHT and after 
withdrawal
3. MtF GiD adults before and after CSHT
4. MtF GiD adults with CSHT vs MtF 
GiD adults without CSHT
Mood states
Newfield et al24 Cross-sectional study FtM adults with CSHT vs FtM adults 
without CSHT
Mental health-related quality of life
Slabbekoorn et al31 Longitudinal study MtF and FtM adults before and after 
CSHT
emotional functioning, affect intensity, 
anger readiness, nonverbal emotional 
expressiveness, and mood states
Blanchard et al34 Cross-sectional study MtF adults Psychological (depression and 
tension) and social (cohabitation and 
involvement) adjustment
Leavitt et al30 Cross-sectional study MtF adults with CSHT vs MtF adults 
without CSHT
Personality-related psychopathology
Abbreviations: CSHT, cross-sex hormonal treatment; FtM, female-to-male; GD, gender dysphoria; GiD, gender identity disorder; MtF, male-to-female.
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Costa and Colizzi
Table 3 Methodological quality of studies of effect of hormonal treatment on mental health in gender dysphoria
Study Defined study 
population
CSHT mean duration CSHT type and dosage Control Comparability of subjects Statistical 
analysis
Mental health 
comorbidity
Attrition Funding or 
sponsorship
Bonierbale 
et al42
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
/ 3 months at least 
for both MtF and FtM
 Not mentioned / No; comparison with 
16 MtF and 38 FtM without 
CSHT
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for age, age on onset, and sexual 
orientation
 Mann–whitney 
t-test, chi-square 
or Fisher’s exact 
tests, and logistic 
regression
 Not mentioned / No available data in 26% of the 
original cohort (N=143) for different 
reasons (N=29 patients not eligible for 
sex reassignment surgery; N=6 with no 
valid MMPi; N=2 missing data)
 Declared
Bouman  
et al38
/ Formal 
diagnosis at a gender 
clinic, criteria not 
mentioned
 Not mentioned / MtF: estrogens, tablet form or patches 
(n=21); sometimes in association with 
cyproterone acetate, spironolactone, or 
finasteride (n=11); and no information provided 
for 17 individuals on CSHT dosage, molecule 
nature, or administration modalities
/ No; comparison with 
33 MtF adults without CSHT
 Significant difference in age of 
referral, coming out, and transitioning; 
sociodemographic characteristics 
matched (ethnic group, employment, 
civil status, and children)
 Chi-square, 
Mann–whitney 
U-test, and 
MANCOvA
 Psychiatric history 
was not exclusion 
criterion, however, clinical 
characteristics (psychiatric 
history and self-harm) 
matched
/ No available data in 7.8% of the 
original cohort (N=77; three did not 
attend appointment and three FtM 
excluded from analysis due to small 
number)
 Declared
Colizzi et al45  GD formal 
diagnosis at a gender 
clinic according 
to DSM-5 SCiD-i 
criteria
 12 months for both 
MtF and FtM
 MtF: transdermal estradiol gel 
(1.84±0.49 mg/d) in association with oral 
cyproterone acetate (100 mg/d) and FtM: iM 
testosterone (250 mg every 26.31±2.68 days)
/ No; normative 
data from a sample of 
1,055 subjects
 Pre/postgroups were the same  t-test  Unstable psychiatric 
comorbidity was exclusion 
criterion 
 0 lost at recruitment or follow-up  Declared
Colizzi et al37  GiD formal 
diagnosis at a gender 
clinic according 
to DSM-iv SCiD-i 
criteria
 12 months for both 
MtF and FtM
 MtF: transdermal estradiol gel 
(1.82±0.53 mg/d) in association with oral 
cyproterone acetate (100 mg/d) and FtM: iM 
testosterone (250 mg every 26.24±2.71 days)
 No  Pre/postgroups were the same  McNemar test 
and t-test
 Unstable psychiatric 
comorbidity was exclusion 
criterion 
 0 lost at recruitment or follow-up  Declared
Fisher et al39  GD formal 
diagnosis at different 
gender clinics 
according to DSM-iv 
criteria
 MtF: 467± 323 days and 
FtM: 1,940±2,595 days
/ MtF: estradiol valerate (n=12), transdermal 
estradiol hemihydrate (n=12), estradiol gel (n=6), 
and oral cyproterone acetate (n=39) and FtM: iM 
testosterone enanthate (n=12), iv testosterone 
undecanoate (n=1), and transdermal 
testosterone (n=9); no information on four FtM 
and CSHT dosage
/ No; comparison with 
57 GD adults without CSHT 
(24 MtF and 33 FtM)
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for gender, age, gender role, and 
surgery
 ANCOvA 
and two-step 
hierarchical linear 
regression
 Not mentioned (mental 
retardation was exclusion 
criterion)
/ 55% of original cohort (N=275) 
were excluded for different reasons 
(CSHT treatment prior to the study, 
disorder of sexual development, 
internalized homophobia, transvestite 
fetishism, mental retardation, dropout 
during the assessment, and completed 
genital reassignment surgery
 Declared
Gómez-Gil 
et al44
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv and iCD-10 
criteria
 Not mentioned  Not mentioned / No; comparison with 
73 GiD adults without CSHT
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for gender, age, education, working/
student status, partnership status, and 
family support
 Multiple linear 
regression
 Not mentioned / No available data in 30% of the 
original cohort (N=277) for different 
reasons (N=17 patients refused to 
participate in the study; N=59 were 
incomplete answers; and N=8 previous 
genital surgery)
 Declared
Heylens  
et al40
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
/ 3–6 months for 
both MtF and FtM
 Not mentioned  No / Pre/postgroups were not the 
same, no mention of possible differences 
between GiD adults completing/not 
completing follow-up evaluation
 Friedman test 
and wilcoxon 
test
/ Personality disorder 
was exclusion criterion
/ No available data in 37% of the 
original cohort (N=90) for different 
reasons (refused to participate, 
attended the clinic once, GiD NOS, 
and comorbidity) and 17.5% of the 
recruited subjects lost at follow-up
 Declared
Colizzi et al14  GiD formal 
diagnosis at a gender 
clinic according 
to DSM-iv SCiD-i 
criteria
 12 months for both 
MtF and FtM
 MtF: transdermal estradiol gel 
(1.77±0.46 mg/d) in association with oral 
cyproterone acetate (100 mg/d) and FtM: iM 
testosterone (250 mg every 27.12±2.64 days)
/ No; normative 
data from a sample of 
645 subjects
 Pre/postgroups were the same  t-test  Psychiatric comorbidity 
was exclusion criterion
 0 lost at recruitment or follow-up  Declared
Gorin-Lazard 
et al36
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
 12 months at least for 
both MtF and FtM
/ MtF: cyproterone acetate followed 
by estrogens combined with antiandrogens 
(luteinizing hormone-releasing hormone analogs) 
and FtM: synthetic progestagens followed by 
testosterone (dosage, molecule nature, and 
administration modalities of CSHT not reported)
/ No; comparison with 
18 GiD adults without CSHT 
(seven MtF and eleven FtM)
 Significant difference in age and sexual 
orientation, but corrected
 Mann–whitney 
U-test and 
multiple linear 
regression
 Psychotic disorder 
and unstable psychiatric 
comorbidity (except 
nonmajor depressive 
disorder) were exclusion 
criteria
 0 lost at recruitment  Declared
(Continued)
Neuropsychiatric Disease and Treatment 2016:12 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
1959
Hormonal treatment and mental health in gender dysphoria
Table 3 Methodological quality of studies of effect of hormonal treatment on mental health in gender dysphoria
Study Defined study 
population
CSHT mean duration CSHT type and dosage Control Comparability of subjects Statistical 
analysis
Mental health 
comorbidity
Attrition Funding or 
sponsorship
Bonierbale 
et al42
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
/ 3 months at least 
for both MtF and FtM
 Not mentioned / No; comparison with 
16 MtF and 38 FtM without 
CSHT
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for age, age on onset, and sexual 
orientation
 Mann–whitney 
t-test, chi-square 
or Fisher’s exact 
tests, and logistic 
regression
 Not mentioned / No available data in 26% of the 
original cohort (N=143) for different 
reasons (N=29 patients not eligible for 
sex reassignment surgery; N=6 with no 
valid MMPi; N=2 missing data)
 Declared
Bouman  
et al38
/ Formal 
diagnosis at a gender 
clinic, criteria not 
mentioned
 Not mentioned / MtF: estrogens, tablet form or patches 
(n=21); sometimes in association with 
cyproterone acetate, spironolactone, or 
finasteride (n=11); and no information provided 
for 17 individuals on CSHT dosage, molecule 
nature, or administration modalities
/ No; comparison with 
33 MtF adults without CSHT
 Significant difference in age of 
referral, coming out, and transitioning; 
sociodemographic characteristics 
matched (ethnic group, employment, 
civil status, and children)
 Chi-square, 
Mann–whitney 
U-test, and 
MANCOvA
 Psychiatric history 
was not exclusion 
criterion, however, clinical 
characteristics (psychiatric 
history and self-harm) 
matched
/ No available data in 7.8% of the 
original cohort (N=77; three did not 
attend appointment and three FtM 
excluded from analysis due to small 
number)
 Declared
Colizzi et al45  GD formal 
diagnosis at a gender 
clinic according 
to DSM-5 SCiD-i 
criteria
 12 months for both 
MtF and FtM
 MtF: transdermal estradiol gel 
(1.84±0.49 mg/d) in association with oral 
cyproterone acetate (100 mg/d) and FtM: iM 
testosterone (250 mg every 26.31±2.68 days)
/ No; normative 
data from a sample of 
1,055 subjects
 Pre/postgroups were the same  t-test  Unstable psychiatric 
comorbidity was exclusion 
criterion 
 0 lost at recruitment or follow-up  Declared
Colizzi et al37  GiD formal 
diagnosis at a gender 
clinic according 
to DSM-iv SCiD-i 
criteria
 12 months for both 
MtF and FtM
 MtF: transdermal estradiol gel 
(1.82±0.53 mg/d) in association with oral 
cyproterone acetate (100 mg/d) and FtM: iM 
testosterone (250 mg every 26.24±2.71 days)
 No  Pre/postgroups were the same  McNemar test 
and t-test
 Unstable psychiatric 
comorbidity was exclusion 
criterion 
 0 lost at recruitment or follow-up  Declared
Fisher et al39  GD formal 
diagnosis at different 
gender clinics 
according to DSM-iv 
criteria
 MtF: 467± 323 days and 
FtM: 1,940±2,595 days
/ MtF: estradiol valerate (n=12), transdermal 
estradiol hemihydrate (n=12), estradiol gel (n=6), 
and oral cyproterone acetate (n=39) and FtM: iM 
testosterone enanthate (n=12), iv testosterone 
undecanoate (n=1), and transdermal 
testosterone (n=9); no information on four FtM 
and CSHT dosage
/ No; comparison with 
57 GD adults without CSHT 
(24 MtF and 33 FtM)
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for gender, age, gender role, and 
surgery
 ANCOvA 
and two-step 
hierarchical linear 
regression
 Not mentioned (mental 
retardation was exclusion 
criterion)
/ 55% of original cohort (N=275) 
were excluded for different reasons 
(CSHT treatment prior to the study, 
disorder of sexual development, 
internalized homophobia, transvestite 
fetishism, mental retardation, dropout 
during the assessment, and completed 
genital reassignment surgery
 Declared
Gómez-Gil 
et al44
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv and iCD-10 
criteria
 Not mentioned  Not mentioned / No; comparison with 
73 GiD adults without CSHT
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for gender, age, education, working/
student status, partnership status, and 
family support
 Multiple linear 
regression
 Not mentioned / No available data in 30% of the 
original cohort (N=277) for different 
reasons (N=17 patients refused to 
participate in the study; N=59 were 
incomplete answers; and N=8 previous 
genital surgery)
 Declared
Heylens  
et al40
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
/ 3–6 months for 
both MtF and FtM
 Not mentioned  No / Pre/postgroups were not the 
same, no mention of possible differences 
between GiD adults completing/not 
completing follow-up evaluation
 Friedman test 
and wilcoxon 
test
/ Personality disorder 
was exclusion criterion
/ No available data in 37% of the 
original cohort (N=90) for different 
reasons (refused to participate, 
attended the clinic once, GiD NOS, 
and comorbidity) and 17.5% of the 
recruited subjects lost at follow-up
 Declared
Colizzi et al14  GiD formal 
diagnosis at a gender 
clinic according 
to DSM-iv SCiD-i 
criteria
 12 months for both 
MtF and FtM
 MtF: transdermal estradiol gel 
(1.77±0.46 mg/d) in association with oral 
cyproterone acetate (100 mg/d) and FtM: iM 
testosterone (250 mg every 27.12±2.64 days)
/ No; normative 
data from a sample of 
645 subjects
 Pre/postgroups were the same  t-test  Psychiatric comorbidity 
was exclusion criterion
 0 lost at recruitment or follow-up  Declared
Gorin-Lazard 
et al36
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
 12 months at least for 
both MtF and FtM
/ MtF: cyproterone acetate followed 
by estrogens combined with antiandrogens 
(luteinizing hormone-releasing hormone analogs) 
and FtM: synthetic progestagens followed by 
testosterone (dosage, molecule nature, and 
administration modalities of CSHT not reported)
/ No; comparison with 
18 GiD adults without CSHT 
(seven MtF and eleven FtM)
 Significant difference in age and sexual 
orientation, but corrected
 Mann–whitney 
U-test and 
multiple linear 
regression
 Psychotic disorder 
and unstable psychiatric 
comorbidity (except 
nonmajor depressive 
disorder) were exclusion 
criteria
 0 lost at recruitment  Declared
(Continued)
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Table 3 (Continued)
Study Defined study 
population
CSHT mean duration CSHT type and dosage Control Comparability of subjects Statistical 
analysis
Mental health 
comorbidity
Attrition Funding or 
sponsorship
Gómez-Gil 
et al35
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv and iCD-10 
criteria
 MtF: 11 years and FtM: 
4.7 years
 MtF: oral estrogens (conjugated estrogens 
1.8–2.4 mg/d or estradiol valerate 2–4 mg/d) 
or transdermal estradiol patches (3 mg twice 
per week, delivering 100 mg/d), generally in 
association with oral cyproterone acetate 
(25–50 mg/d) and FtM: iM testosterone 
(1,000 mg every 10–14 weeks), or daily 
transdermal testosterone gel (50 mg/d)
/ No; comparison with 
67 GiD adults without CSHT 
(29 MtF and 38 FtM)
 Significant difference in age, MtF 
prevalence, and level of education 
(without CSHT , CSHT), but 
these were corrected. Other 
sociodemographic characteristics 
matched (living arrangements, sexual 
orientation, and employment status)
 ANOvA/ 
ANCOvA, 
chi-square, 
and Pearson’s 
correlation
 Not mentioned / No available data in 6.5% of 
original cohort (N=200)
 Declared
Gorin-Lazard 
et al43
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv MiNi criteria
 12 months at least for 
both MtF and FtM
/ MtF: antiandrogens along with estrogens 
and FtM: synthetic progestagens with 
testosterone (dosage, molecule nature, and 
administration modalities of CSHT not reported)
/ No; comparison with 
17 GiD adults without CSHT 
(six MtF and eleven FtM); 
controls from a normative 
sample of 3,656 subjects
 Sociodemographic characteristics 
matched (age for GiD adults with and 
without CSHT and age and sex for GiD 
adults and non-GiD controls)
 Mann–whitney 
test, multiple 
linear regression, 
and t-test
 Psychotic disorder 
and unstable psychiatric 
comorbidity (except 
non major depressive 
disorder) were exclusion 
criteria
/ No available data in 9% of original 
cohort (N=67)
 Declared
Gómez-Gil 
et al41
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
 12 months at least for 
both MtF and FtM
 Not mentioned / No; comparison with 
84 GiD adults without CSHT 
(38 MtF and 46 FtM)
 Not mentioned  t-test  Not mentioned / No available data in 36% of the 
original cohort (N=254) for different 
reasons (N=24 patients failed to meet 
GiD DSM-iv criteria; N=24 patients 
were administered the MMPi instead of 
MMPi-2; and N=43 were missing data)
 Not 
declared
Miles et al29  GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
1. / 3–12 months for 
both MtF and FtM
2. / at least 8 weeks 
of withdrawal after at 
least 28 months of CSHT 
for both MtF and FtM
3. / 6–15 months for 
both MtF and FtM
4. 
 Conjugated equine estrogens (1.25–7.5 mg/d) 
or ethinyl estradiol (10–15 µg/d), sometimes 
in association with cyproterone acetate 
(50–150 mg/d) or medroxyprogesterone 
acetate (15 mg/d)
/ No
4. Comparison with MtF 
without CSHT
1., 2., and 3.  Pre/postgroups were 
the same
4.  Significant difference in age, not 
corrected
 MANOvAs 
and Pearson’s 
correlation
 Not mentioned  0 lost at recruitment or follow-up  Declared
Newfield  
et al24
 Not mentioned / ,5 years for the 
majority of FtM (n=203)
 Not mentioned / No; comparison with 
117 FtM adults without CSHT
/ Sociodemographic characteristics 
not reported; analyses were controlled 
for income and education
 ANOvA/
ANCOvA
 Not mentioned / No available data in 18% of the 
original cohort (N=446) for different 
reasons (not from the US, identified 
as female/no gender information, no 
information on quality of life or CSHT)
 Not 
declared
Slabbekoorn 
et al31
/ Formal 
diagnosis at a gender 
clinic, criteria not 
mentioned
/ 14 weeks for both 
MtF and FtM
 MtF: oral cyproterone acetate (50 mg/twice 
a day) in combination with oral ethinyl estradiol 
(0.05 mg/twice a day, n=32) or 17β-estradiol 
plasters (0.1 mg/d, n=22); FtM: iM testosterone 
esters (250 mg/2 weeks, n=42),or oral 
undecanoate testosterone (200 mg/d, n=5)
 No  Pre/postgroups were the same  ANOvA and 
t-test
 Not mentioned  0 lost at recruitment or follow-up  Not 
declared
Blanchard 
et al34
/ Formal 
diagnosis at a gender 
clinic, criteria not 
mentioned
 Not mentioned  Not mentioned / No; comparison with 
21 MtF adults without CSHT
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for age and social feminization
 Multiple 
regression
/ Not mentioned 
(gender complaint-related 
psychotic delusion was 
exclusion criterion)
/ No available data in 44% of the 
original cohort (N=98) for different 
reasons (N=42 patients excluded 
because of not expressing – clear – 
homosexual orientation; N=1 excluded 
due to Klinefelter’s syndrome)
 Not 
declared
Leavitt et al30  Not mentioned  12 months at least / Oral conjugated estrogens and 
medroxyprogesterone (cyclically each month in a 
dose sufficient to inhibit spontaneous erections)
/ No; comparison with 
19 MtF adults without CSHT
 Sociodemographic characteristics 
matched (age and education)
 t-test and 
Pearson’s 
correlation
 Not mentioned  0 lost at recruitment  Not 
declared
Note: , good quality; /, fair quality; , poor quality. 
Abbreviations: ANCOvA, analysis of covariance; ANOvA, analysis of variance; CSHT, cross-sex hormonal treatment; DSM, Diagnostic and Statistical Manual of Mental 
Disorders; FtM, female to male; GD, gender dysphoria; GID, gender identity disorder; ICD-10, international classification of diseases – 10th revision; IM, intramuscular; IV, 
intravenous; MANCOvA, multivariate analysis of covariance; MiNi, mini-international neuropsychiatric interview; MMPi-2, Minnesota Multiphasic Personality inventory-2; 
MtF, male to female; NOS, not otherwise specified; SCID-I, Structured Clinical Interview for DSM I.
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Table 3 (Continued)
Study Defined study 
population
CSHT mean duration CSHT type and dosage Control Comparability of subjects Statistical 
analysis
Mental health 
comorbidity
Attrition Funding or 
sponsorship
Gómez-Gil 
et al35
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv and iCD-10 
criteria
 MtF: 11 years and FtM: 
4.7 years
 MtF: oral estrogens (conjugated estrogens 
1.8–2.4 mg/d or estradiol valerate 2–4 mg/d) 
or transdermal estradiol patches (3 mg twice 
per week, delivering 100 mg/d), generally in 
association with oral cyproterone acetate 
(25–50 mg/d) and FtM: iM testosterone 
(1,000 mg every 10–14 weeks), or daily 
transdermal testosterone gel (50 mg/d)
/ No; comparison with 
67 GiD adults without CSHT 
(29 MtF and 38 FtM)
 Significant difference in age, MtF 
prevalence, and level of education 
(without CSHT , CSHT), but 
these were corrected. Other 
sociodemographic characteristics 
matched (living arrangements, sexual 
orientation, and employment status)
 ANOvA/ 
ANCOvA, 
chi-square, 
and Pearson’s 
correlation
 Not mentioned / No available data in 6.5% of 
original cohort (N=200)
 Declared
Gorin-Lazard 
et al43
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv MiNi criteria
 12 months at least for 
both MtF and FtM
/ MtF: antiandrogens along with estrogens 
and FtM: synthetic progestagens with 
testosterone (dosage, molecule nature, and 
administration modalities of CSHT not reported)
/ No; comparison with 
17 GiD adults without CSHT 
(six MtF and eleven FtM); 
controls from a normative 
sample of 3,656 subjects
 Sociodemographic characteristics 
matched (age for GiD adults with and 
without CSHT and age and sex for GiD 
adults and non-GiD controls)
 Mann–whitney 
test, multiple 
linear regression, 
and t-test
 Psychotic disorder 
and unstable psychiatric 
comorbidity (except 
non major depressive 
disorder) were exclusion 
criteria
/ No available data in 9% of original 
cohort (N=67)
 Declared
Gómez-Gil 
et al41
 GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
 12 months at least for 
both MtF and FtM
 Not mentioned / No; comparison with 
84 GiD adults without CSHT 
(38 MtF and 46 FtM)
 Not mentioned  t-test  Not mentioned / No available data in 36% of the 
original cohort (N=254) for different 
reasons (N=24 patients failed to meet 
GiD DSM-iv criteria; N=24 patients 
were administered the MMPi instead of 
MMPi-2; and N=43 were missing data)
 Not 
declared
Miles et al29  GiD formal 
diagnosis at a gender 
clinic according to 
DSM-iv criteria
1. / 3–12 months for 
both MtF and FtM
2. / at least 8 weeks 
of withdrawal after at 
least 28 months of CSHT 
for both MtF and FtM
3. / 6–15 months for 
both MtF and FtM
4. 
 Conjugated equine estrogens (1.25–7.5 mg/d) 
or ethinyl estradiol (10–15 µg/d), sometimes 
in association with cyproterone acetate 
(50–150 mg/d) or medroxyprogesterone 
acetate (15 mg/d)
/ No
4. Comparison with MtF 
without CSHT
1., 2., and 3.  Pre/postgroups were 
the same
4.  Significant difference in age, not 
corrected
 MANOvAs 
and Pearson’s 
correlation
 Not mentioned  0 lost at recruitment or follow-up  Declared
Newfield  
et al24
 Not mentioned / ,5 years for the 
majority of FtM (n=203)
 Not mentioned / No; comparison with 
117 FtM adults without CSHT
/ Sociodemographic characteristics 
not reported; analyses were controlled 
for income and education
 ANOvA/
ANCOvA
 Not mentioned / No available data in 18% of the 
original cohort (N=446) for different 
reasons (not from the US, identified 
as female/no gender information, no 
information on quality of life or CSHT)
 Not 
declared
Slabbekoorn 
et al31
/ Formal 
diagnosis at a gender 
clinic, criteria not 
mentioned
/ 14 weeks for both 
MtF and FtM
 MtF: oral cyproterone acetate (50 mg/twice 
a day) in combination with oral ethinyl estradiol 
(0.05 mg/twice a day, n=32) or 17β-estradiol 
plasters (0.1 mg/d, n=22); FtM: iM testosterone 
esters (250 mg/2 weeks, n=42),or oral 
undecanoate testosterone (200 mg/d, n=5)
 No  Pre/postgroups were the same  ANOvA and 
t-test
 Not mentioned  0 lost at recruitment or follow-up  Not 
declared
Blanchard 
et al34
/ Formal 
diagnosis at a gender 
clinic, criteria not 
mentioned
 Not mentioned  Not mentioned / No; comparison with 
21 MtF adults without CSHT
 Sociodemographic characteristics for 
GiD adults with and without CSHT not 
reported, however, analyses controlled 
for age and social feminization
 Multiple 
regression
/ Not mentioned 
(gender complaint-related 
psychotic delusion was 
exclusion criterion)
/ No available data in 44% of the 
original cohort (N=98) for different 
reasons (N=42 patients excluded 
because of not expressing – clear – 
homosexual orientation; N=1 excluded 
due to Klinefelter’s syndrome)
 Not 
declared
Leavitt et al30  Not mentioned  12 months at least / Oral conjugated estrogens and 
medroxyprogesterone (cyclically each month in a 
dose sufficient to inhibit spontaneous erections)
/ No; comparison with 
19 MtF adults without CSHT
 Sociodemographic characteristics 
matched (age and education)
 t-test and 
Pearson’s 
correlation
 Not mentioned  0 lost at recruitment  Not 
declared
Note: , good quality; /, fair quality; , poor quality. 
Abbreviations: ANCOvA, analysis of covariance; ANOvA, analysis of variance; CSHT, cross-sex hormonal treatment; DSM, Diagnostic and Statistical Manual of Mental 
Disorders; FtM, female to male; GD, gender dysphoria; GID, gender identity disorder; ICD-10, international classification of diseases – 10th revision; IM, intramuscular; IV, 
intravenous; MANCOvA, multivariate analysis of covariance; MiNi, mini-international neuropsychiatric interview; MMPi-2, Minnesota Multiphasic Personality inventory-2; 
MtF, male to female; NOS, not otherwise specified; SCID-I, Structured Clinical Interview for DSM I.
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and body uneasiness. Key findings are reported in Table 2, 
and a brief synopsis of them is reported later.
effect of cross-sex hormonal treatment on 
depression, mood states, and self-esteem
Depression and its features have been the most extensively 
investigated mental health-related parameters in gender 
dysphoria individuals receiving hormonal treatment. The 
first study to investigate this issue was carried out in 1983.34 
This cross-sectional study assessed male-to-female (MtF) 
individuals’ psychological adjustment depending on their 
hormonal treatment status. The research did not find any 
significant difference in terms of depressive symptoms 
between MtFs with and without hormonal treatment.34 In 
a second study, Slabbekoorn et al31 asked female-to-male 
(FtM) individuals to keep a mood diary during their testos-
terone administration. Results indicated no mood changes 
when assessing depressed mood and other mood-related 
para meters from baseline to after the fourth testosterone 
injection.31 Miles et al29 used a unique design to disentangle 
the hormonal treatment contribution to mood in gender dys-
phoria. Using both independent groups (longitudinal study) 
and repeated measure (cross-sectional study) designs, this 
study consistently indicated that hormone-treated MtFs are 
more composed and confident. Authors also tested for the 
effect of hormonal treatment withdrawal and duration on 
mood. Intriguingly, they reported no significant association.29 
In recent years, four more studies have investigated the asso-
ciation between hormonal treatment and depression, using 
commonly used questionnaires/scales.35–38 Apart from a 
study,38 which reported no significant differences in terms 
of depression (it only investigated MtFs), the remaining 
studies reported lower depressive symptoms in gender 
dysphoria individuals receiving hormonal treatment.35–37 
Two of these studies also assessed self-esteem, reporting 
higher levels of self-esteem due to the hormonal treatment 
intervention.36,38
effect of cross-sex hormonal treatment 
on anxiety and tension
Different from depression, anxiety has been investigated 
only recently, with three studies addressing this aspect over 
the last 5 years.35,37,38 All these three investigations (two 
cross-sectional studies and one longitudinal one) have con-
sistently reported a reduction in symptoms of anxiety among 
individuals receiving hormone therapy. A previous research 
had studied tension as a measure of psychological adjustment, 
reporting no significant differences between MtFs with and 
without hormonal treatment.34
effect of cross-sex hormonal treatment 
on global and personality-related 
psychopathology
This review has identified three recent studies about the 
effect of cross-sex hormonal treatment on a global measure 
of psychopathology.37,39,40 Intriguingly, all these studies 
used the same questionnaire. However, while two studies 
described a significant decrease in global psychopathology 
occurring after the initiation of hormone therapy,37,40 a third 
one did not find any difference between hormone-treated and 
nonhormone-treated individuals.39 Interestingly, according to 
the authors, their negative finding may be attributable to the 
restricted range and low levels of psychopathology observed 
in their sample.
Three other studies investigated personality-related psy-
chopathology as a function of cross-sex hormonal treatment, 
using a similar methodology.30,41,42 Using a common measure 
of personality, this body of research has suggested a reduc-
tion in personality-related psychopathology among gender 
dysphoria individuals receiving hormone therapy. However, 
as one study focused only on MtF individuals30 and a second 
study reported hormonal treatment to be beneficial only in 
MtF and not in FtM individuals,41 there is still little evidence 
to suggest a positive effect of cross-sex hormonal treatment 
on FtM individuals’ personality-related psychopathology.42 
Leavitt et al30 also indicated that the hormone-treated MtF 
individuals’ overall personality-related psychopathology 
tends to approximate the norms for male populations and 
negatively correlates with the hormone therapy duration.
effect of cross-sex hormonal treatment 
on mental health-related quality of life
The first study to investigate the quality of life among gender 
dysphoria individuals receiving hormonal treatment was 
performed in 2006 on a large sample of FtM individuals.24 
With ~250 FtMs receiving cross-sex hormonal treatment, 
this study sample represents the largest one identified in this 
systematic review. The research reported higher emotional, 
social, and mental quality of life in hormone-treated FtM 
adults, with hormonal treatment duration associated with 
higher emotional quality of life.24 Three more recent studies 
confirmed a better psychosocial and mental quality of life 
in both MtFs and FtMs receiving hormone therapy.36,43,44 
One study also compared hormone-treated individuals with 
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a control group, reporting a higher mental health-related 
quality of life in gender dysphoria individuals.43
effect of cross-sex hormonal treatment 
on dissociative symptoms
To date, only one study has investigated the prevalence of 
dissociative symptoms among gender dysphoria individuals 
receiving cross-sex hormonal treatment.45 Results of this 
longitudinal study suggest that suffering from dissociative 
symptoms may be a common clinical feature in the context 
of untreated gender dysphoria. Interestingly, this research 
indicated a significant reduction in gender dysphoria 
individuals’ dissociative symptoms after the beginning of 
cross-sex hormonal treatment. It is worth reporting that the 
high prevalence of dissociative symptoms among untreated 
gender dysphoria individuals was greatly due to the gender-
related sense of strangeness. This issue could explain why 
the dissociative experience was less intense when gender 
dysphoria individuals received hormone therapy. The unease 
with the biological sex and the aversion to the corresponding 
sex-specific body forms belong by definition to the gender 
dysphoria diagnosis.2 Therefore, authors argued whether dis-
sociation represents a genuine feature of gender dysphoria 
rather than a clinically relevant pathological manifestation, 
highlighting the need for additional/exclusion criteria for a 
differential diagnosis.45
effect of cross-sex hormonal treatment 
on psychosocial, interpersonal, and 
emotional functioning
Psychosocial functioning has been the domain receiving most 
attention after depression in hormone-treated individuals. 
Different aspects have been investigated, such as emotional31 
and social components.34,38 Also two studies have investigated 
a global measure of psychosocial functioning.36,37 Impact of 
hormone therapy on emotional functioning appeared to be 
different in MtF and FtM individuals, with more generally 
positive effects in MtF and some undesirable effects in FtM 
individuals.31 While Blanchard et al34 did not find any effect 
of hormone therapy on social adjustment, a more recent study 
has identified less problems with socialization and interper-
sonal functioning in gender dysphoria individuals receiving 
hormone therapy.38 Finally, mixed results have emerged from 
studies investigating global psychosocial functioning, with a 
study reporting less functional impairment after the beginning 
of hormone therapy37 and another one finding no significant 
differences as a result of hormonal treatment.36
effect of cross-sex hormonal treatment 
on social distress, perceived stress, and 
body uneasiness
This review identified three studies specifically analyz-
ing distress intensity among gender dysphoria individuals 
and how it could be influenced by the hormonal treatment 
intervention.14,35,39 These studies used the following three dif-
ferent measures of distress: 1) social distress, ie, avoidance 
and subjective distress about social interactions; 2) perceived 
stress, ie, perception of social life experiences as stressful 
and unpredictable/uncontrollable; and 3) body uneasiness, 
ie, gender-related distress and discomfort. Using a cross-
sectional design, Gómez-Gil et al35 reported that gender dys-
phoria individuals who have not received hormonal treatment 
show higher levels of social distress than those receiving 
cross-sex hormones. Consistent with these findings,35 in a 
second study, hormone-treated gender dysphoria individuals 
showed lower perceived stress, which overlapped with that 
found in the normative sample.14 The last study addressed 
the impact of hormonal treatment on body-related distress, 
suggesting a gender-specific effect. In fact, MtF individu-
als’ body uneasiness was lower in the context of cross-sex 
hormonal treatment, and the reduction correlated negatively 
with the cumulative dose of estradiol.39 Instead, FtM subjects 
did not appear to benefit from the hormone therapy in terms 
of body uneasiness. Authors themselves commented on it as 
an unexpected finding, which could be due to the individual’s 
still unsatisfactory comfort with the body at a private/personal 
level rather than involving a social dimension.39
Risk of systematic bias across studies
While generally well designed, results mentioned earlier need 
to be considered in light of certain limitations. Apart from one 
study,39 all the others came from only one clinic and some of 
them had a relatively small sample size. Most importantly, as 
no study used a blinded randomized controlled trial design, 
results could have also different explanations because of 
the study design(s). Moreover, type and dosage of cross-
sex hormonal treatment were often not reported, and when 
reported, there was poor consistency across studies. The same 
weakness applied to hormone therapy duration. While dif-
ferences between analyzed groups were generally taken into 
account, more than half the studies did not mention/control 
for psychiatric comorbidity, which could have represented 
a critical bias in this kind of investigation. Finally, while 
studies were generally strict on the defined study population 
(formal diagnosis according to DSM criteria used at the time 
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of the study), recruitment/follow-up attrition represented an 
issue for some of the studies identified in this review.
Discussion
This is the first systematic review of all studies examining 
the effect of cross-sex hormonal treatment on mental health 
and psychosocial well-being in gender dysphoria. A previ-
ous review has mainly focused on the psychosocial outcome 
of gender dysphoria individuals receiving sex reassignment 
surgery.27 After the publication of that review, the literature 
has seen an increasing number of studies specifically inter-
ested in whether sex hormones induce any improvement in 
terms of mental health and psychosocial well-being. Overall, 
this review demonstrates that cross-sex hormonal treatment 
has definite effects on mental health, generally ameliorating 
gender dysphoria individuals’ well-being at different levels. 
Taking into account the risks of bias reported earlier, cross-
sex hormonal treatment does not seem to affect any of the 
parameters investigated, except emotional functioning, with a 
reported higher prevalence of aggressive emotions and lower 
affect intensity in FtMs receiving hormonal treatment.31
More specifically, when treated with hormone therapy, 
gender dysphoria individuals reported less anxiety,35,37,38 
dissociation,45 perceived stress,14 social distress,35 and higher 
mental health-related quality of life24,36,43,44 and self-esteem.36,38 
Also, compared to FtM individuals, MtF individuals seemed 
to benefit more in terms of body uneasiness,39 emotional 
functioning,31 and personality-related psychopathology.30,41,42 
More mixed results emerged from studies investigating 
other mental health-related dimensions. In particular, 
recent studies suggested reduced depressive symptoms in 
hormone-treated gender dysphoria individuals,35–37 despite 
previous evidence of no association between cross-sex 
hormonal treatment and depression among MtF34 and FtM 
individuals.31 Similarly, global psychopathology appeared 
to be reduced in two studies,8,37 while a third one did not 
detect any change.39 Finally, while two studies indicated 
less functional impairment37 and reduced problems with 
socialization and interpersonal functioning in gender dys-
phoria individuals receiving hormone therapy,38 two other 
studies did not find any effect of hormone therapy on social 
adjustment34 and psychosocial functioning.36 Negative 
findings generally came from studies involving a cross-
sectional design. On the contrary, the few longitudinal 
studies identified in this review were consistent in indicat-
ing an association between hormonal treatment and better 
mental health.14,29,31,37,40,45 Conducting observations of the 
same subjects over a period of time, longitudinal studies can 
establish sequences of events and better detect changes in 
the characteristics of the target population, also due to their 
higher statistical power.
Some of the studies included in this review offered a 
comparison of hormone-treated gender dysphoria individu-
als to normal range values of normative data for a general 
population. Interestingly, all these studies indicated that after 
the beginning of the cross-sex hormonal treatment, gender 
dysphoria individuals express distress levels similar to the 
general population in several mental health-related dimen-
sions, including perceived stress,14 dissociative symptoms,45 
personality-related psychopathology,30 mental health-related 
quality of life,43 and global psychopathology.40 These results 
are in-line with the majority of the previous studies, indicating 
that hormone therapy decreases the psychiatric comorbidities 
often associated with a lack of hormonal treatment.27
The finding of a reduced mental distress in the context of 
hormone-treated gender dysphoria may have several explana-
tions. The question arising is whether cross-sex hormones 
exert a direct effect on distress levels, implying a biological 
explanation for their reduction, or rather indirectly elicit a 
better mental health, implying a psychological mechanism 
possibly related to the physical changes. Biologically, sex 
hormones may exert different effects on mental distress. 
Specifically, estrogens may increase mental distress, mak-
ing individuals more prone to anxiety and depression.46 
Instead, androgens can reduce mental distress, promoting 
feelings of euphoria and energy47 and also eliciting stress 
and hostility.48 As a consequence, mental distress should 
increase in MtF individuals as a consequence of the bio-
logical effect of estrogens. Conversely, due to the biological 
effects of androgens, hormone therapy should induce both 
positive and negative effects on FtM individuals’ mental 
distress, depending on the mental health parameters evalu-
ated. The only finding in support of a biological mechanism 
for the observed changes in mental distress is the increase 
in the prevalence of aggressive emotions among hormone-
treated FtM individuals.31 Nevertheless, studies included in 
this review found that hormonal treatment has a positive 
effect on both MtF and FtM individuals’ mental health. 
In addition, this amelioration is more pronounced in MtF 
individuals, who should be more negatively affected by 
the cross-sex hormonal treatment intervention according to 
the biological explanation. In light of all this evidence, this 
review does not support the hypothesis of a direct effect of 
hormone therapy on mental well-being in gender dysphoria. 
Instead, the distress reduction might be an indirect effect 
of hormone therapy, as already hypothesized by Kuiper 
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and Cohen-Kettenis.32 Mental distress may be considered a 
reaction to the nonsatisfaction arising by the incongruence 
between the individual’s experienced gender and biological 
sex. Cross-sex hormonal treatment is supposed to mitigate 
such incongruence, inducing desired physical changes that 
could eventually be responsible for the individual’s better 
mental state and psychological well-being. In other words, 
thanks to the body changes obtained, gender dysphoria indi-
viduals may experience a reduction in their mental distress. 
In addition, other psychological explanations support the 
hypothesis of an indirect effect of hormonal treatment on 
mental well-being. Due to incongruence between their physi-
cal appearance and internal experience, nonhormone-treated 
gender dysphoria individuals may face major difficulties in 
managing their gender identity at a social level. Hormonal 
treatment may reinforce the gender affirmation with a better 
social recognition. This would explain why in some studies 
hormonal treatment seems to have a beneficial effect on the 
social dimension rather than on the private dimension of men-
tal well-being.39 Finally, as delaying hormonal treatment has 
been reported to often disappoint gender dysphoria individu-
als, also increasing their distress,37,45 we cannot exclude that 
accessing care and receiving eligibility for hormone therapy 
may help in reducing distress, representing an acceptance of 
the individual’s needs and requirements. In order to promote 
the highest standards of health for individuals seeking gender 
transitioning, the importance of facilitating access to care 
and reducing barriers across countries and cultures cannot 
be overemphasized. Several factors have been identified, 
which can affect gender dysphoria individuals’ access to 
care and eventually lead to a nonsatisfactory outcome, such 
as stigma, violence, fear of being seen as different, lack of/
inadequate access to specialized health care professionals 
and/or services, and poor access to health care pathway-
related information.49
Conclusion
This review suggests that gender dysphoria-related mental 
distress may benefit from hormonal treatment intervention. 
Even recognizing the suffering of nonhormone-treated gender 
dysphoria individuals, which represents a possible risk factor 
for more severe or full-syndromal psychiatric disorders,12 
mental distress in gender dysphoria may be considered as 
a transient reaction to the nonsatisfaction connected to the 
incongruent body image and not necessarily a stable psy-
chiatric comorbidity. In this perspective, timely hormonal 
treatment intervention represents a crucial issue in gender 
dysphoria individuals’ mental health-related outcome.
Acknowledgments
The authors would like to thank all patients and colleagues 
met during the years of clinical research activity. A special 
thank goes to the Gender Unit at the University of Bari, Bari, 
Italy, and the Gender Identity Development Service at the 
Tavistock and Portman NHS Foundation Trust, London, UK. 
There was no funding source for this study.
Disclosure
The authors report no conflicts of interest in this work.
References
 1. American Psychiatric Association (APA). Diagnostic and Statistical 
Manual of Mental Disorders: DSM-III. 3rd ed. Washington, DC: 
American Psychiatric Association; 1980.
 2. American Psychiatric Association (APA). Diagnostic and Statistical 
Manual of Mental Disorders: DSM-5. 5th ed. Arlington, VA: American 
Psychiatric Association; 2013.
 3. American Psychiatric Association (APA). Diagnostic and Statistical 
Manual of Mental Disorders: DSM-IV. 4th ed. Washington, DC: 
American Psychiatric Association; 1994.
 4. American Psychiatric Association (APA). Diagnostic and Statistical 
Manual of Mental Disorders: DSM-IV-TR. 4th ed. Washington, DC: 
American Psychiatric Association; 2000.
 5. Drescher J. Queer diagnoses: parallels and contrasts in the history 
of homosexuality, gender variance, and the diagnostic and statistical 
manual. Arch Sex Behav. 2010;39(2):427–460.
 6. à Campo J, Nijman H, Merckelbach H, Evers C. Psychiatric comorbidity 
of gender identity disorders: a survey among Dutch psychiatrists. Am 
J Psychiatry. 2003;160(7):1332–1336.
 7. Hepp U, Kraemer B, Schnyder U, Miller N, Delsignore A. Psy-
chiatric comorbidity in gender identity disorder. J Psychosom Res. 
2005;58(3):259–261.
 8. Heylens G, Elaut E, Kreukels BP, et al. Psychiatric characteristics in 
transsexual individuals: multicentre study in four European countries. 
Br J Psychiatry. 2014;204(2):151–156.
 9. Gómez-Gil E, Trilla A, Salamero M, Godás T, Valdés M. Sociodemo-
graphic, clinical, and psychiatric characteristics of transsexuals from 
Spain. Arch Sex Behav. 2009;38(3):378–392.
 10. Hoshiai M, Matsumoto Y, Sato T, et al. Psychiatric comorbidity among 
patients with gender identity disorder. Psychiatry Clin Neurosci. 2010; 
64(5):514–519.
 11. Fisher AD, Bandini E, Casale H, et al. Sociodemographic and clinical 
features of gender identity disorder: an Italian multicentric evaluation. 
J Sex Med. 2013;10(2):408–419.
 12. Dhejne C, Van Vlerken R, Heylens G, Arcelus J. Mental health and gen-
der dysphoria: a review of the literature. Int Rev Psychiatry. 2016;28(1): 
44–57.
 13. Sohn M, Bosinski HA. Gender identity disorders: diagnostic and surgi-
cal aspects. J Sex Med. 2007;4(5):1193–1207.
 14. Colizzi M, Costa R, Pace V, Todarello O. Hormonal treatment reduces 
psychobiological distress in gender identity disorder, independently of 
the attachment style. J Sex Med. 2013;10(12):3049–3058.
 15. Byne W, Bradley SJ, Coleman E, et al. Report of the American Psychi-
atric Association task force on treatment of gender identity disorder. 
Arch Sex Behav. 2012;41(4):759–796.
 16. Cohen-Kettenis PT, van Goozen SH. Sex reassignment of adolescent 
transsexuals: a follow-up study. J Am Acad Child Adolesc Psychiatry. 
1997;36(2):262–271.
 17. Rehman J, Lazer S, Benet AE, Schaefer LC, Melman A. The reported 
sex and surgery satisfactions of 28 postoperative male-to-female trans-
sexual patients. Arch Sex Behav. 1999;28(1):71–89.
Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing 
on concise rapid reporting of clinical or pre-clinical studies on a 
range of neuropsychiatric and neurological disorders. This journal 
is indexed on PubMed Central, the ‘PsycINFO’ database and CAS, 
and is the official journal of The International Neuropsychiatric 
 Association (INA). The manuscript management system is completely 
online and includes a very quick and fair peer-review system, which 
is all easy to use. Visit http://www.dovepress.com/testimonials.php to 
read real quotes from published authors.
Neuropsychiatric Disease and Treatment 2016:12submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
1966
Costa and Colizzi
 18. Lawrence AA. Factors associated with satisfaction or regret follow-
ing male-to-female sex reassignment surgery. Arch Sex Behav. 2003; 
32(4):299–315.
 19. Bodlund O, Armelius K. Self-image and personality traits in gender 
identity disorders: an empirical study. J Sex Marital Ther. 1994;20(4): 
303–317.
 20. Wolfradt U, Neumann K. Depersonalization, self-esteem and body 
image in male-to-female transsexuals compared to male and female 
controls. Arch Sex Behav. 2001;30(3):301–310.
 21. Kraemer B, Delsignore A, Schnyder U, Hepp U. Body image and 
transsexualism. Psychopathology. 2008;41(2):96–100.
 22. Weyers S, Elaut E, De Sutter P, et al. Long-term assessment of the 
physical, mental, and sexual health among transsexual women. J Sex 
Med. 2009;6(3):752–760.
 23. Rakic Z, Starcevic V, Maric J, Kelin K. The outcome of sex reassign-
ment surgery in Belgrade: 32 patients of both sexes. Arch Sex Behav. 
1996;25(5):515–525.
 24. Newfield E, Hart S, Dibble S, Kohler L. Female-to-male transgender 
quality of life. Qual Life Res. 2006;15(9):1447–1457.
 25. Kuhn A, Bodmer C, Stadlmayr W, Kuhn P, Mueller MD, Birkhäuser M. 
Quality of life 15 years after sex reassignment surgery for transsexual-
ism. Fertil Steril. 2009;92(5):1685–1689.
 26. Ainsworth TA, Spiegel JH. Quality of life of individuals with and 
without facial feminization surgery or gender reassignment surgery. 
Qual Life Res. 2010;19(7):1019–1024.
 27. Murad MH, Elamin MB, Garcia MZ, et al. Hormonal therapy and 
sex reassignment: a systematic review and meta-analysis of quality of 
life and psychosocial outcomes. Clin Endocrinol (Oxf). 2010;72(2): 
214–231.
 28. Slabbekoorn D, van Goozen SH, Megens J, Gooren LJ, Cohen-
Kettenis PT. Activating effects of cross-sex hormones on cognitive 
functioning: a study of short-term and long-term hormone effects in 
transsexuals. Psychoneuroendocrinology. 1999;24(4):423–447.
 29. Miles C, Green R, Hines M. Estrogen treatment effects on cognition, 
memory and mood in male-to-female transsexuals. Horm Behav. 2006; 
50(5):708–717.
 30. Leavitt F, Berger JC, Hoeppner JA, Northrop G. Presurgical adjustment 
in male transsexuals with and without hormonal treatment. J Nerv Ment 
Dis. 1980;168(11):693–697.
 31. Slabbekoorn D, Goozen SHV, Gooren LJ, Cohen-Kettenis PT. Effects 
of cross-sex hormone treatment on emotionality in transsexuals. 
Int J Transgend. 2001;5(3):2–18.
 32. Kuiper B, Cohen-Kettenis P. Sex reassignment surgery: a study of 141 
Dutch transsexuals. Arch Sex Behav. 1988;17(5):439–457.
 33. West S, King TS, Carey KN, et al. Systems to rate the strength of 
scientific evidence. Evid Rep Technol Assess (Summ). 2002;47:1–11.
 34. Blanchard R, Clemmensen LH, Steiner BW. Gender reorientation and 
psychosocial adjustment in male-to-female transsexuals. Arch Sex 
Behav. 1983;12(6):503–509.
 35. Gómez-Gil E, Zubiaurre-Elorza L, Esteva I, et al. Hormone-treated 
transsexuals report less social distress, anxiety and depression. 
Psychoneuroendocrinology. 2012;37(5):662–670.
 36. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Hormonal therapy is 
associated with better self-esteem, mood, and quality of life in trans-
sexuals. J Nerv Ment Dis. 2013;201(11):996–1000.
 37. Colizzi M, Costa R, Todarello O. Transsexual patients’ psychiatric 
comorbidity and positive effect of cross-sex hormonal treatment on 
mental health: results from a longitudinal study. Psychoneuroendocri-
nology. 2014;39:65–73.
 38. Bouman WP, Claes L, Marshall E, et al. Sociodemographic variables, 
clinical features, and the role of preassessment cross-sex hormones in 
older trans people. J Sex Med. 2016;13(4):711–719.
 39. Fisher AD, Castellini G, Bandini E, et al. Cross-sex hormonal treatment 
and body uneasiness in individuals with gender dysphoria. J Sex Med. 
2014;11(3):709–719.
 40. Heylens G, Verroken C, De Cock S, T’Sjoen G, De Cuypere G. Effects 
of different steps in gender reassignment therapy on psychopathology: 
a prospective study of persons with a gender identity disorder. J Sex 
Med. 2014;11(1):119–126.
 41. Gómez-Gil E, Vidal-Hagemeijer A, Salamero M. MMPI-2 characteris-
tics of transsexuals requesting sex reassignment: comparison of patients 
in prehormonal and presurgical phases. J Pers Assess. 2008;90(4): 
368–374.
 42. Bonierbale M, Baumstarck K, Maquigneau A, et al. MMPI-2 profile of 
French transsexuals: the role of sociodemographic and clinical factors. 
A cross-sectional design. Sci Rep. 2016;6:24281.
 43. Gorin-Lazard A, Baumstarck K, Boyer L, et al. Is hormonal therapy 
associated with better quality of life in transsexuals? A cross sectional 
study. J Sex Med. 2012;9(2):531–541.
 44. Gómez-Gil E, Zubiaurre-Elorza L, de Antonio IE, Guillamon A, 
Salamero M. Determinants of quality of life in Spanish transsexuals 
attending a gender unit before genital sex reassignment surgery. Qual 
Life Res. 2014;23(2):669–676.
 45. Colizzi M, Costa R, Todarello O. Dissociative symptoms in individuals 
with gender dysphoria: is the elevated prevalence real? Psychiatry Res. 
2015;226(1):173–180.
 46. Asscheman H, Gooren LJ, Eklund PL. Mortality and morbidity in 
transsexual patients with cross-gender hormone treatment. Metabolism. 
1989;38(9):869–873.
 47. Su TP, Pagliaro M, Schmidt PJ, Pickar D, Wolkowitz O, Rubinow DR. 
Neuropsychiatric effects of anabolic steroids in male normal volunteers. 
JAMA. 1993;269(21):2760–2764.
 48. King JA, Rosal MC, Ma Y, Reed G. Association of stress, hostility 
and plasma testosterone levels. Neuro Endocrinol Lett. 2005;26(4): 
355–360.
 49. Wylie K, Knudson G, Khan SI, Bonierbale M, Watanyusakul S, Baral S. 
Serving transgender people: clinical care considerations and service 
delivery models in transgender health. Lancet. Epub 2016 Jun 16.
